KTTA•benzinga•
Pasithea Therapeutics Initiates Phase 1/1B Study Of PAS-004 In Adult NF1 Patients, First Patient Expected To Be Dosed In Q2 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga